Articles tagged with Interferons
Interferon-alpha treatment depletes mutant blood stem cells and induces production of infection-fighting white blood cells, potentially benefiting patients with myeloproliferative neoplasms. The study's findings provide new strategies for managing these blood cancers.
Researchers found type III interferons reduce disease severity in autoimmune uveitis by suppressing Th1/Th17 responses and NLRP1/NLRP3 inflammasome activation. This study identifies IFN-λ as a promising immunomodulatory agent for autoimmune uveitis.
A multicenter analysis of 920 patients with compensated cirrhosis found that interferon therapy was not associated with a higher risk of serious complications compared to standard treatment. Milder side effects were more common and required closer monitoring.
A systematic review and meta-analysis of pegylated interferon treatment found HBsAg decline at week 24 to be the best predictor of functional cure, while on-treatment HBV RNA levels were most reliable for HBeAg loss. Novel virologic markers were less effective than traditional indicators.
Researchers created lab-grown human nasal tissue to study the defense mechanisms against rhinoviruses. They found that cells in the nasal lining produce interferons, which induce a coordinated antiviral defense, controlling viral replication and reducing damage.
Researchers found that immature neutrophils migrate into inflamed tissues upon stimulation by interferon-γ, suppressing inflammation and reducing tissue damage. In humans, these cells also produce interleukin-10, which increases in the blood of COVID-19 patients.
A new cytokine delivery platform reprograms the tumor microenvironment to enhance CAR-T cell function in preclinical brain cancer models. The strategy leads to a broader immune response that inhibits tumor growth and extends host survival, even in mice with only a fraction of cells expressing the CAR-targeted antigen.
A study from The University of Osaka found that specific white blood cells and an inflammation protein can predict relapse of autoimmune blood vessel disease. Researchers analyzed neutrophils in patients' blood to identify a subpopulation involved in disease progression.
A synthetic retinoic acid-inducible gene I (RIG-I) agonist RNA has been shown to induce innate immune signaling and death of hepatocellular carcinoma cells in vitro. The addition of recombinant interferon-b potentiated this cell death, suggesting a potential new mechanism for treating patients with liver cancer.
A new study using a novel mouse strain expressing Halo-tagged SOCS1 reveals that the inhibitor needs to exceed a threshold level to suppress GM-CSF and IFN-gamma signaling. The findings emphasize SOCS1's crucial function in modulating cytokine signaling.
Researchers found that cellular RNA molecules help regulate antiviral signaling by activating the MAVS signalosome. This signaling pathway is crucial for coordinating immune responses against virus invasion. The study's findings suggest a potential role for RNA-based therapeutics in combating infections and autoimmune diseases.
New discoveries by NYU researchers find that impaired regulatory T cells are a key contributor to Sjögren's disease in both mice and humans. Calcium signaling also plays a crucial role in the development of the autoimmune disorder, which affects glands producing saliva and tears.
Researchers found Itaconate stimulates immune cells to produce anti-viral proteins called interferons by blocking an enzyme called SDH, offering a potential therapy for autoimmune and infectious diseases.
Researchers analyzed mice infected with herpes virus and found that removing STING from nociceptors resulted in significant reduction of pain without affecting inflammation or viral load. The discovery may apply to other viral and bacterial infections, including COVID-19.
Researchers have discovered how a protein linked to the human immune system wards off HIV-1 and herpes simplex virus-1 by assembling structures in the cell that lure in viruses and trap them. This discovery offers new avenues for antiviral therapies and could be used to devise strategies to combat these viruses.
Researchers from Osaka University discovered that Ikaros binds to Foxp3 to inhibit the expression of target genes, including Ifng, in regulatory T cells. This interaction is crucial for maintaining immune homeostasis and preventing autoimmune disorders.
Researchers found auto-antibodies against type I interferons in severe and critical COVID-19 patients, compromising their immune response. This discovery highlights the importance of detecting these auto-antibodies in regular health checkups to better prepare for viral infections.
Researchers discovered that hnRNPM prevents errors in protein synthesis by blocking pseudo splice sites, maintaining accurate mRNA molecules. In its absence, cancer cells exhibit increased cryptic splicing, triggering interferon immune responses and potentially driving disease progression.
Researchers found that specific combinations of interferon proteins, including I, II, and III, are associated with various lupus symptoms like skin rashes, kidney inflammation, and joint pain. Elevated levels of these interferons can lead to severe disease presentations.
A new study found extensive alternative splicing of messenger RNA in untreated multiple sclerosis patients compared to healthy controls. Interferon-ß therapy corrected dysregulated alternative splicing, linking it to future clinical exacerbations.
Researchers at the University of Alberta have discovered a new class of antiviral drugs that stimulate interferon production to reverse the effect of SARS-CoV-2 on cells. The study shows that these drugs can significantly reduce the amount of virus found in the lungs and prevent severe symptoms.
A new study has identified a strategy used by early-stage cancer cells to evade the immune system. By turning on the gene SOX17, these cells create an immunosuppressive environment that prevents them from being detected. This gene helps cancer cells ignore immune messages and grow in the presence of an immune system.
Research identifies interferon gamma (IFN-γ) as a potential biomarker for Long COVID fatigue and highlights an immunological mechanism underlying the disease. High levels of IFN-γ persisted in some patients for up to 31 months, coinciding with symptom resolution after vaccination.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
A new MU study highlights the protective role of innate lymphoid cells and interferons in reducing neurological effects of Brucellosis. The findings could lead to improved diagnostics and therapies for neurobrucellosis, a condition that can cause long-term neurological complications.
Researchers discovered that STING, a critical immune regulator, can act as an ion channel to control immune responses. This new function allows STING to translate danger signals into ion flow, activating various defense mechanisms.
A clinical trial found that interferon can help reduce the spread of COVID-19 from a positive person to their household contacts. The study tracked 1,172 participants and showed that interferon treatment reduced viral load in households with high viral loads. However, it did not reduce disease severity.
A machine-learning study has found that individual characteristics, including age and weight, determine which drug combinations most effectively reduce COVID-19 recurrence rates. The study used real-world data from a hospital in China and identified unique treatment combinations for different demographic groups.
Scientists from Institut Pasteur and Inserm discovered that CD4 T cells can remotely neutralize tumor cells by producing interferon gamma, offering new hopes for patients with incomplete responses to CAR T cell therapy. This study raises the possibility of personalized treatment approaches using larger quantities of CD4 CAR T cells.
Researchers at the National Institutes of Health have found that immunotherapy can prevent the progression of low-grade lymphomatoid granulomatosis to high-grade disease. The treatment significantly improves survival rates for patients with the rare precancerous condition, with a median overall survival of over 20 years.
Researchers found that immune cells play a key role in hypertension, weakening blood vessel walls and damaging the blood-brain barrier. Inhibiting inflammatory messengers may be a new therapeutic target for treating hypertension.
A Brazilian study found that a strain of brewer's yeast can act as a preventive against asthma in male mice. Daily administration of the probiotic at a dose of 10 billion CFU/mL significantly reduced bronchial hypersensitivity and inflammation. However, airway and lung inflammation was not significantly reduced by lower doses.
Researchers review approaches to inhibit IL-15 and its receptor, exploring effects on inflammatory autoimmune diseases, transplantation, infectious diseases, and cancer. Clinical testing of humanized anti-IL-15 monoclonal antibodies reveals promising therapeutic potential.
Researchers found that certain gene signaling pathways, such as interferon γ and beta-catenin, can lead to tumor hyperprogression after immunotherapy. Targeting these pathways may prevent hyperprogression in preclinical models.
A Phase I/II study found tofacitinib effective in improving skin and organ issues in systemic sclerosis patients. The drug was well-tolerated, with minimal impact on T-cells, suggesting potential repurposing for treatment.
Researchers at CU Anschutz Medical Campus investigated SARS-CoV-2 variant interactions with diverse interferons, finding the virus has adapted to evade this key front-line defense. The study suggests COVID-19 clinical trials on interferons may need to be reinterpreted based on circulating variants.
A team of researchers at the University of Pittsburgh used computational modeling to investigate the immune response to avian flu. They found that the levels of interferon may be responsible for its more severe presentation and could hold the key to treating it.
Research reveals cytokine involvement in IgA nephropathy by increasing aberrantly O-glycosylated IgA1 production. The study provides insights into clinical trials using cytokines as therapeutic targets and future directions for treatment.
Researchers from Dartmouth's Geisel School of Medicine found a significant rate of new TB infections among Tanzanian adolescents. The study used serial testing and identified transient, persistent, and irregular conversions between positive and negative IGRA test results.
Researchers developed a novel nanobody-based detection method for recombinant human interferon α2b (rhIFNα2b), which has a lower detection limit than existing methods. The assay's operation time was shortened from two days to a few minutes, making it suitable for rapid market counterfeit detection and early diagnosis of hepatitis.
The study found that gut microbiota releases membrane vesicles containing bacterial DNA, which triggers the cytosolic cGAS-STING-IFN-I axis to protect distal organs against viral infections. Antibiotic treatment impairs this ability, making mice more susceptible to viral infections.
Researchers found that normal-appearing lupus skin contains the same inflammatory signals as skin with rashes, suggesting a primed state for inflammation. The study's findings provide new insights into how UV light triggers rashes in lupus patients and highlight the potential for precision medicine in treating the disease.
Researchers from Trinity College Dublin have discovered how SARS and MERS coronaviruses block the induction of antiviral proteins, preventing a strong immune response. This finding has potential implications for developing new therapeutic options to treat COVID-19 and future deadly coronaviruses.
A new study by University of Southampton researchers found that a third COVID-19 vaccination improves immune responses in blood cancer patients. The study showed that 92% of patients without recent anti-CD20 treatment had improved antibody responses after the third dose.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
The IL-1RL2 cytokine has been implicated in the development of inflammatory diseases such as psoriasis and IBD, while also promoting the expression of inflammatory cytokines and chemokines. Its role in controlling infection, including COVID-19 pathology, highlights its potential as a target for therapeutic interventions.
A new study reveals that the Omicron variant is sensitive to inhibition by the interferon response, an unspecific immune reaction present in all body cells. This provides the first explanation for why COVID-19 patients infected with Omicron are less likely to experience severe disease.
Researchers at UCSF have identified a new potential drug target, BRD2, which regulates the ACE2 receptor, a key entry point for SARS-CoV-2. Blocking production of BRD2 prevents virus from infecting various human cell types.
A study from Michigan Medicine found that people with type 2 diabetes are more likely to develop a cytokine storm during coronavirus infection due to the enzyme SETDB2. Administering interferon beta increased SETDB2 and decreased inflammatory cytokines in diabetic mice, offering potential therapy for severe COVID-19.
A Michigan Medicine study found that altering interferon kappa levels in mice with psoriasis-like lesions reduced disease severity. The research suggests using therapies to modulate interferon states may limit inflammation in psoriasis patients.
A study by Yale researchers found that the common cold virus can trigger an immune response that halts replication of the SARS-CoV-2 virus. Exposure to rhinovirus was shown to protect against COVID-19 infection, with the immune system responding rapidly to the threat.
Researchers have created human cells containing a green fluorescent protein (GFP) that can report on the innate immune response to viral infections. This new tool enables convenient investigation of the human innate immune response to coronaviruses and other viruses.
The audiobook memoir tells the remarkable story of Dr. Jan Vilcek's life, from hiding from Nazis to researching cytokines and interferon that led to infliximab's development. The Vilcek Foundation partnered with actor Daniel K. Isaac to narrate the audiobook, available on Audible, iTunes, and Amazon.
A UC Riverside virologist has received a $1.9 million award to investigate how the Zika virus beats human defenses, with the goal of developing a vaccine and antiviral drug. The research aims to understand how the virus triggers the degradation of STAT2, a key host factor in activating interferons.
Researchers discovered a rare genetic variant that dampens innate immunity to COVID-19, increasing the risk of severe disease in younger men. Genetic testing and interferon treatment may benefit affected individuals.
Research from INRS identifies ways to prevent coronavirus infection in the central nervous system, using protein S cleavage and innate immunity. The study suggests two potential therapeutic approaches to limit viral spread and severity of neurological disorders.
Researchers at Duke University have discovered that exercising lab-grown human muscle can directly counteract the damaging effects of chronic inflammation, particularly from interferon gamma. The study shows that muscle cells take anti-inflammatory actions independently of other cell types or tissues.
Researchers at Sanford Burnham Prebys Medical Discovery Institute identified MDA-5 as the primary sensor in human lungs that detects SARS-CoV-2. The protein recognizes replicating viruses and activates interferon, a key player in the body's defense against viral invasion.
Researchers discovered a new, shorter form of ACE2 that lacks the viral binding site, contradicting previous studies. This finding supports the use of interferon-based treatments for COVID-19 patients.
A clinical trial found that inhaled delivery of interferon beta-1a to hospitalised COVID-19 patients in the UK reduced severe disease and death rates. Those receiving SNG001 were more than twice as likely to recover from infection compared to placebo recipients.